{"id":7114,"date":"2019-12-13T17:39:12","date_gmt":"2019-12-13T12:09:12","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7114"},"modified":"2025-05-08T12:56:07","modified_gmt":"2025-05-08T07:26:07","slug":"fragile-x-syndrome-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market","title":{"rendered":"Fragile X Syndrome Market"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f82b0495639\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f82b0495639\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market\/#AI-driven_treatment_approach_and_growing_Fragile_X_Syndrome_market_size\" >AI-driven treatment approach and growing Fragile X Syndrome market size<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market\/#What_is_Fragile_X_Syndrome_FXS\" >What is Fragile X Syndrome (FXS)?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market\/#Fragile_X_Syndrome_Epidemiology\" >Fragile X Syndrome Epidemiology<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market\/#Fragile_X_Syndrome_Diagnosis\" >Fragile X Syndrome Diagnosis<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market\/#Fragile_X_Syndrome_Treatment_Market\" >Fragile X Syndrome Treatment Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market\/#Fragile_X_syndrome_market\" >Fragile X syndrome market<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<p><!--StartFragment--><\/p>\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AI-driven_treatment_approach_and_growing_Fragile_X_Syndrome_market_size\"><\/span>AI-driven treatment approach and growing Fragile X Syndrome market size<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Healx Pharma has recently partnered with Boehringer Ingelheim to advance\nthe treatment market and invest in R&amp;D related to rare neurological\ndisorders. <\/p>\n\n\n\n<p>Under the deal signed, Healx Artificial Intelligence (AI) drug discovery\nplatform- Healnet will help in identifying the indications that can be treated\nwith the use of therapies and drugs from the Boehringer Ingelheim\u2019s pipeline. <\/p>\n\n\n\n<p>AI-powered biotechnology company, Healx has proven that its AI-driven Healnet has identified around eight drugs that can be repurposed to offer a potential and efficient cure for <strong>Rare neurological disorders<\/strong> such as FXS. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Fragile_X_Syndrome_FXS\"><\/span><strong>What is Fragile X Syndrome (FXS)? <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Fragile X syndrome <\/strong>(FXS)\nis a genetic condition. Caused by the mutations in the gene- <strong>Fragile X\nmental retardation 1 <\/strong>(FMR1). The condition is also known as <strong>Martin-Bell\nsyndrome.<\/strong><\/p>\n\n\n\n<p>The gene <strong>FMR1<\/strong> is usually responsible for transcribing a protein, namely, <strong>Fragile X mental retardation protein<\/strong> (FMRP), which is required for normal protein development. The <strong><a href=\"https:\/\/www.delveinsight.com\/blog\/are-rare-diseases-truly-rare\/\">rare genetic disease<\/a><\/strong>&#8211; Fragile X Syndrome occurs in people who fail to make this protein.&nbsp; <\/p>\n\n\n\n<p>Fragile X syndrome symptoms comprise of a range of developmental disorders hampering learning abilities, causing cognitive impairments. The patients also suffer from delayed speech and language development. In addition to speech impairment, FXS patients also face mild to moderate intellectual disability. Interestingly enough, the FXS symptoms are more severe in boys as compared to girls. People afflicted with this rare genetic disorder might suffer from mild to moderate intellectual disability whereas, as per NCBI, about one-third of female FXS patients have intellectual disabilities. <\/p>\n\n\n\n<p>Moreover, Young FXS patients may also have anxiety and hyperactivity behavior such as fidgeting and can be impulsive in nature. About one-third of individuals afflicted with FXS, as per NCBI, may show autistic behaviors such as hand-flapping and uncomfortable in making eye contact.&nbsp; <\/p>\n\n\n\n<p>Attention deficit disorder (ADD) is another common Fragile X Syndrome symptom, which results in reduced attention and concentration on any task. They also have problems with loud noises and bright lights referred to as sensory integration problems. Moreover, Seizures affect around 15 percent of the males and 5 percent of the females with Fragile X syndrome. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fragile_X_Syndrome_Epidemiology\"><\/span><strong>Fragile X Syndrome Epidemiology <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Fragile X syndrome has been found in all major ethnic groups and races.<\/p>\n\n\n\n<p>As per the <strong>Orphanet<\/strong> <strong>registry<\/strong>, worldwide <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/fragile-x-syndrome-pipeline-insight\">Fragile X syndrome prevalence<\/a><\/strong> is estimated at approximately 1\/4000-1\/5000.&nbsp;&nbsp; disorder than females. <\/p>\n\n\n\n<p>Fragile X syndrome is the most commonly inherited cause of mental retardation in males. It afflicts 1 in 4000 boys, however, in girls the <strong>Fragile X Syndrome incidence<\/strong> is 1 in 8000.&nbsp; So, the FXS is double in males as compared to females. The higher male preponderance of FXS is due to the genetic makeup of a human being. Since, women have two copies of the X chromosome, about four times as many females are altered <strong>Fragile X Carriers <\/strong>when compared with males (1:250 females and 1:1000 males). In the case of altered Fragile X carrier males, the premutation is passed on to the daughters and not sons, however, if the female is the carrier of altered Fragile X gene, the premutation can be passed to both.&nbsp; <\/p>\n\n\n\n<p>According to the estimates by the Centers for Disease Control and Prevention, FXS incidence is around <strong>1.4 per 10,000 males<\/strong> and <strong>0.9 per 10,000 females<\/strong>. <\/p>\n\n\n\n<p>Moreover, talking about the FXS epidemiological trends geography-wise, about 1 in 4000 males and 1 in 6000-8000 females are affected by FXS in the US.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fragile_X_Syndrome_Diagnosis\"><\/span><strong>Fragile X Syndrome Diagnosis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>FXS diagnosis is based on clinical testing since physical symptoms are quite similar to other indications and are often mild or absent. Testing a person\u2019s DNA from a blood test to evaluate the functioning of the FMR1 gene is often carried out in Autistic patients or with intellectual deficiency. <\/p>\n\n\n\n<p>The trends reveal that the average age of the FXS diagnosis for boys ranges between 35 to 37 months whereas the average age for girls is 42 months.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fragile_X_Syndrome_Treatment_Market\"><\/span><strong>Fragile X Syndrome Treatment Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p style=\"background-color:#b1ceda\" class=\"has-background\"><strong>At present, Fragile X syndrome has no cure. <\/strong><\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/fragile-x-syndrome-fxs-market\">Fragile X syndrome treatment market<\/a><\/strong> is still at the infancy stage due to the lack of any approved standard Fragile X syndrome treatment. <\/p>\n\n\n\n<p>At present, the FXS treatment market comprises a number of treatment options that are <strong>symptomatic<\/strong> in nature. The available FXS therapies help in improving the quality of the lives of the <strong>Fragile X syndrome patients<\/strong>. Lifestyle modifications such as special education, speech therapies, occupational, sensory integration training, and behavior modification programs also help in improving overall conditions of the FXS patients. Additionally, recommendation of Genetic counseling to affected FXS individuals and their families is also common. <\/p>\n\n\n\n<p>Prescription of medications such as <strong>Sympatholytic<\/strong> including Clonidine, Propranolol, and <strong>Antidepressants<\/strong> like Tricyclic Antidepressants (TCAs) is also given to FXS patients. In addition to these, administration of <strong>monoamine oxidase inhibitors<\/strong> (MAOI\u2019s), <strong>Selective Serotonin Reuptake Inhibitors<\/strong> (SSRIs), such as Sertraline, Escitalopram, Duloxetine, and Paroxetine) and <strong>Mood Stabilizers<\/strong>, such as Lithium, Carbamazepine, Valproic acid, Clonazepam, Risperidone is also prevalent in Fragile X syndrome patients. <\/p>\n\n\n\n<p>Due to a dearth of substantial effective Fragile X syndrome, there and\nincreasing Fragile X syndrome prevalence, as estimates DelveInsight\u2019s analysts,\nthe Fragile X syndrome Market is expected to grow considerably. There are many\nresearchers who are actively working towards developing treatments for the\ndisease. FRAXA, an organization actively searching for an FXS cure, raises\nfunds and supports extensive efforts for FXS. Some researchers also focus on\nnew targeted treatments for FXS that can target the mGluR5 pathway\nabnormalities in FXS.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fragile_X_syndrome_market\"><\/span><strong>Fragile X syndrome market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The dynamics of the <strong>Fragile X syndrome market<\/strong> are anticipated to change in the coming years owing to the rising awareness of the disease, incremental healthcare spending across the world and expected launch of emerging therapies during the forecast period of 2018-2027. <\/p>\n\n\n\n<p>Pharma players and biotech companies across the globe are working towards the development of new Fragile X syndrome treatment therapies. Some of the <strong>Fragile X syndrome Companies <\/strong>in the <strong>Fragile X syndrome therapeutic market <\/strong>at the global level are<strong> Zynerba Pharmaceuticals<\/strong>, <strong>Seaside Therapeutics<\/strong>, <strong>Ovid Therapeutics<\/strong>, <strong>Neuren Pharmaceuticals<\/strong>, <strong>Tetra Discovery Partners<\/strong> and <strong>Neurotrope Bioscience<\/strong> and many more. <\/p>\n\n\n\n<p>Despite some of the companies recently shifted their focus towards this indication, other companies such as Healx and Boehringer Ingelheim are also working  to create a significant influence on the market size during the forecast period.<\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/fragile-x-syndrome-pipeline-insight\">Fragile X syndrome pipeline<\/a><\/strong> as several therapies such as <strong>ZYN002<\/strong> (Zynerba Pharmaceuticals), <strong>STX209<\/strong> (Seaside Therapeutics), <strong>OV101<\/strong> (Ovid Therapeutics), <strong>Trofinetide<\/strong> (Neuren Pharmaceuticals), <strong>BPN14770<\/strong> (Tetra Discovery Partners), and <strong>Bryostatin<\/strong> (Neurotrope Bioscience), which will positively impact the Fragile X syndrome market during the study period (2017-2028).<\/p>\n\n\n\n<p>Moreover, Fragile X syndrome research for a better understanding of anxiety and the precursors to behavioral will further accelerate the manufacturing of the Fragile X syndrome therapy market. <\/p>\n\n\n<p><!--EndFragment--><\/p>","protected":false},"excerpt":{"rendered":"<p>AI-driven treatment approach and growing Fragile X Syndrome market size Healx Pharma has recently partnered with Boehringer Ingelheim to advance the treatment market and invest in R&amp;D related to rare neurological disorders. Under the deal signed, Healx Artificial Intelligence (AI) drug discovery platform- Healnet will help in identifying the indications that can be treated with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7115,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[7318,750,17892,7319,7320,17893,751,17896,17897,16847,502,992,17895,2341,17894],"industry":[17225],"therapeutic_areas":[17238,17245,17234],"class_list":["post-7114","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-fragile-x-mental-retardation-protein","tag-fragile-x-syndrome","tag-fragile-x-syndrome-epidemiology","tag-fragile-x-syndrome-incidence","tag-fragile-x-syndrome-market","tag-fragile-x-syndrome-treatment-market","tag-fragile-x-syndrome-pipeline-insights","tag-neuren-pharmaceuticals","tag-neurotrope-bioscience","tag-ovid-therapeutics","tag-rare-disease","tag-rare-indication","tag-seaside-therapeutics","tag-tetra-discovery-partners","tag-zynerba-pharmaceuticals","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-neurology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Fragile X Syndrome Market | FXS Marrket | Delveinsight<\/title>\n<meta name=\"description\" content=\"The dynamics of the Fragile X syndrome market are anticipated to change in the coming years owing to the rising FXS awareness and a strong pipeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fragile X Syndrome Market | FXS Marrket | Delveinsight\" \/>\n<meta property=\"og:description\" content=\"The dynamics of the Fragile X syndrome market are anticipated to change in the coming years owing to the rising FXS awareness and a strong pipeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-13T12:09:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T07:26:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/13172041\/fragile-x-syndrome.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fragile X Syndrome Market | FXS Marrket | Delveinsight","description":"The dynamics of the Fragile X syndrome market are anticipated to change in the coming years owing to the rising FXS awareness and a strong pipeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market","og_locale":"en_US","og_type":"article","og_title":"Fragile X Syndrome Market | FXS Marrket | Delveinsight","og_description":"The dynamics of the Fragile X syndrome market are anticipated to change in the coming years owing to the rising FXS awareness and a strong pipeline.","og_url":"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-12-13T12:09:12+00:00","article_modified_time":"2025-05-08T07:26:07+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/13172041\/fragile-x-syndrome.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market","url":"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market","name":"Fragile X Syndrome Market | FXS Marrket | Delveinsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/13172041\/fragile-x-syndrome.jpg","datePublished":"2019-12-13T12:09:12+00:00","dateModified":"2025-05-08T07:26:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The dynamics of the Fragile X syndrome market are anticipated to change in the coming years owing to the rising FXS awareness and a strong pipeline.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/fragile-x-syndrome-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/13172041\/fragile-x-syndrome.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/13172041\/fragile-x-syndrome.jpg","width":772,"height":482,"caption":"Fragile X Syndrome Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/13172041\/fragile-x-syndrome-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Fragile X mental retardation protein<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Fragile X syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Fragile X Syndrome Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Fragile X Syndrome incidence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Fragile X syndrome market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Fragile X Syndrome Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Fragile X Syndrome-Pipeline Insights<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Neuren Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Neurotrope Bioscience<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Ovid Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Rare Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Rare Indication<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Seaside Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Tetra Discovery Partners<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Zynerba Pharmaceuticals<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Fragile X mental retardation protein<\/span>","<span class=\"advgb-post-tax-term\">Fragile X syndrome<\/span>","<span class=\"advgb-post-tax-term\">Fragile X Syndrome Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Fragile X Syndrome incidence<\/span>","<span class=\"advgb-post-tax-term\">Fragile X syndrome market<\/span>","<span class=\"advgb-post-tax-term\">Fragile X Syndrome Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Fragile X Syndrome-Pipeline Insights<\/span>","<span class=\"advgb-post-tax-term\">Neuren Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Neurotrope Bioscience<\/span>","<span class=\"advgb-post-tax-term\">Ovid Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Rare Disease<\/span>","<span class=\"advgb-post-tax-term\">Rare Indication<\/span>","<span class=\"advgb-post-tax-term\">Seaside Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Tetra Discovery Partners<\/span>","<span class=\"advgb-post-tax-term\">Zynerba Pharmaceuticals<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Dec 13, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Dec 13, 2019 5:39 pm","modified":"Updated on May 8, 2025 12:56 pm"},"featured_img_caption":"Fragile X Syndrome Market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7114"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7114\/revisions"}],"predecessor-version":[{"id":31946,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7114\/revisions\/31946"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7115"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7114"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7114"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}